Business Description
MaxCyte Inc
NAICS : 334510
SIC : 3845
ISIN : US57777K1060
Description
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.98 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.42 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 6 | |||||
| Beneish M-Score | 19.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 4.1 | |||||
| 3-Year EBITDA Growth Rate | -47.2 | |||||
| 3-Year EPS without NRI Growth Rate | -32.3 | |||||
| 3-Year FCF Growth Rate | -18.7 | |||||
| 3-Year Book Growth Rate | 60 | |||||
| Future 3-5Y Total Revenue Growth Rate | 13.29 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 18.87 | |||||
| 9-Day RSI | 22.89 | |||||
| 14-Day RSI | 26.96 | |||||
| 6-1 Month Momentum % | 40.82 | |||||
| 12-1 Month Momentum % | -9.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.65 | |||||
| Quick Ratio | 9.97 | |||||
| Cash Ratio | 9.43 | |||||
| Days Inventory | 846.07 | |||||
| Days Sales Outstanding | 78.56 | |||||
| Days Payable | 102.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -21.9 | |||||
| Shareholder Yield % | -0.47 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.52 | |||||
| Operating Margin % | -117.57 | |||||
| Net Margin % | -92.39 | |||||
| FCF Margin % | -61.8 | |||||
| ROE % | -15.66 | |||||
| ROA % | -13.77 | |||||
| ROIC % | -80.94 | |||||
| ROC (Joel Greenblatt) % | -116.68 | |||||
| ROCE % | -18.6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.22 | |||||
| PB Ratio | 1.67 | |||||
| Price-to-Tangible-Book | 1.68 | |||||
| EV-to-EBIT | -4.82 | |||||
| EV-to-EBITDA | -5.28 | |||||
| EV-to-Forward-EBITDA | -10.6 | |||||
| EV-to-Revenue | 5.67 | |||||
| EV-to-Forward-Revenue | 5.51 | |||||
| EV-to-FCF | -9.16 | |||||
| Price-to-Projected-FCF | 5.27 | |||||
| Price-to-Net-Current-Asset-Value | 2.52 | |||||
| Price-to-Net-Cash | 2.95 | |||||
| Earnings Yield (Greenblatt) % | -20.74 | |||||
| FCF Yield % | -6.65 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers